# Grifols SA > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Grifols SA). ## Overview Grifols SA is a biopharmaceutical company focused on plasma-derived medicines and related services for patients with chronic and rare diseases. Its business includes the collection and processing of human plasma, the manufacture of therapies and diagnostic products, and the operation of plasma donation and manufacturing infrastructure across multiple markets. ## Products & services • Plasma-derived medicines for chronic and rare diseases • Plasma collection and donation center operations • Blood-plasma diagnostics and transfusion solutions • Hospital and specialty healthcare products • Patient and healthcare-professional education materials - **Plasma-derived therapeutics** (60%) — Medicines manufactured from human plasma for chronic, rare and life-threatening conditions. - **Immunology and specialty treatments** (15%) — Therapies used in specialty care settings, often prescribed by physicians and hospitals. - **Diagnostics and transfusion medicine** (10%) — Products and solutions used in blood screening, testing and transfusion workflows. - **Plasma collection services** (15%) — Operation of plasma donation centers and related donor-support infrastructure. - Plasma-derived medicines for chronic and rare diseases - Plasma collection and donation center operations - Blood-plasma diagnostics and transfusion solutions - Hospital and specialty healthcare products - Patient and healthcare-professional education materials ## Customers Grifols sells primarily to healthcare professionals, hospitals, blood banks and healthcare systems that prescribe, stock or administer plasma-derived therapies. It also serves plasma donors through its collection network and supports wholesalers, distributors and group purchasing organizations that help place its products in care settings. In the United States it also conducts patient education and awareness activities, but its medicines are prescription-based and not direct-to-consumer products. - **Hospitals and healthcare providers** (primary) — Buy plasma-derived medicines and diagnostics for inpatient, outpatient and specialty treatment use. - **National health systems and blood banks** (primary) — Procure transfusion-related products and supply solutions for public healthcare needs. - **Wholesalers and distributors** (secondary) — Purchase and distribute Grifols products into hospital and specialty-care channels. - **Plasma donors** (primary) — Provide plasma at collection centers; they are a supply-side customer/participant group critical to operations. - **Patients with rare diseases** (primary) — Indirect end users of prescribed plasma-derived therapies used in ongoing treatment. - Hospitals and healthcare providers buying prescription plasma therapies - National health systems and blood banks procuring transfusion products - Wholesalers, distributors and GPOs placing products in care channels - Plasma donors participating in collection-center networks - Patients with chronic or rare diseases treated through physicians ## Geography Grifols operates globally, with commercial activities and stakeholder engagement spanning the United States, Europe and other international markets. The company’s plasma collection, manufacturing, regulatory and commercial footprint makes geography important because donation access, health-system reimbursement and regulatory approvals differ by country. The reports also show specific U.S. direct-to-consumer educational initiatives alongside broad healthcare-professional marketing worldwide. - Global commercial footprint across healthcare markets - United States includes direct-to-consumer educational initiatives - Europe is important for manufacturing, regulation and sales - Regulatory approvals affect plasma centers and product launches - Healthcare-system access and reimbursement vary by country ## Strategy Grifols’ strategy centers on maintaining a trusted plasma-supply network, supporting physicians and patients with education, and securing approvals for manufacturing facilities and new indications. The company also emphasizes compliance-led marketing, stakeholder engagement and regulatory interaction because its business depends on prescription access, plasma-center authorization and quality standards. - **Protect and grow plasma collection capacity** (medium-term) — Plasma supply is the core input to the company’s therapies and determines product availability. - **Advance regulatory approvals and compliance** (short-term) — Manufacturing and commercialization depend on health-authority approvals and ongoing quality oversight. - **Build physician and patient awareness** (short-term) — Prescribed therapies rely on diagnosis, access and clinical understanding rather than consumer advertising. - Expand and protect plasma supply through donor engagement - Support prescribing through physician and patient education - Maintain strict compliance in global promotional activities - Secure regulatory approvals for centers, facilities and indications - Strengthen investor and stakeholder communication ## Risks Grifols faces supply-chain and operational risk because its therapies depend on sufficient plasma collection, center authorization and quality-controlled manufacturing. It is also exposed to regulatory, litigation and compliance risk given the medical nature of its products, the scrutiny around promotional practices, and the need for approvals across multiple jurisdictions. - **Plasma supply disruption** [high] — The business depends on a steady flow of donor plasma to manufacture medicines. - **Regulatory approval delays** [high] — Plasma centers, facilities and new indications require health-authority approvals. - **Compliance and marketing scrutiny** [medium] — The company promotes prescription products and must keep materials balanced and lawful. - **Goodwill and asset impairment** [high] — Management must test intangible and non-current assets for recoverability using estimates. - Plasma-supply disruption could constrain therapy production - Regulatory delays can affect centers, facilities and launches - Compliance failures may trigger sanctions or reputational damage - Impairment risk exists for goodwill and long-lived assets - Cross-border healthcare access and reimbursement vary materially ## Accounting The most important accounting judgments relate to goodwill, intangible assets and other non-current assets, where recoverability depends on cash-flow forecasts, growth assumptions and discount rates. The company also highlights valuation issues in business combinations and corporate transactions, which can materially affect reported assets and future impairment charges. - **Goodwill and intangible impairment** — Can create material non-cash charges if forecasts weaken. - **Fair value in business combinations** — Affects purchase accounting and future amortization or impairment. - **Useful lives of assets** — Changes reported operating costs over time. - **Contingent obligations and legal matters** — May influence provisions and disclosed liabilities. - Goodwill and intangible asset impairment testing - Useful lives and recoverable value of non-current assets - Fair value estimates in business combinations - Discount-rate and cash-flow assumptions in valuation - Potential judgment in contractual obligations and contingencies --- *Last updated: 2026-09-28T12:03:52.934129+00:00*